Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: A cost-utility analysis

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1825-1832

  Liberato, N L ^a   Rognoni, C ^b   Rubrichi, S ^b   Quaglini, S ^b   Marchetti, M ^c   Gorlia, T ^d   Licitra, L ^e   Vermorken, J B ^f  

^a Azienda Ospedaliera della Provincia di Pavia   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Ospedale Cardinal Massaia   (Italy)

^d EORTC DATA CENTER   (Belgium)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cost effectiveness; Cost utility; Docetaxel; Head and neck cancer; PF; TPF

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE ASSOCIATION; DOSIMETRY; DRUG COST; HEAD AND NECK CANCER; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FLUOROURACIL; HEAD AND NECK NEOPLASMS; INDUCTION CHEMOTHERAPY; MARKOV CHAINS; MONTE CARLO METHOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TAXOIDS;

EID: 84864301687     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr545     Document Type: Article

References (25)

1. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363(1): 24-35.
2. Schwartz SM, Daling JR, Doody DR et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998; 90: 1626-1636.
3. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720.
4. Andl T, Kahn T, Pfuhl A et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998; 58: 5-13.
5. Wiest T, Schwarz E, Enders C et al. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002; 21: 1510-1517.
6. van Houten VM, Snijders PJ, van den Brekel MW et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001; 93: 232-235.
7. Hafkamp HC, Speel EJ, Haesevoets A et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 2003; 107: 394-400.
8. Mork J, Lie AK, Glattre E et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-1131.
9. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121: 1813-1820.
10. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.
11. Reimers N, Kasper HU, Weissenborn SJ et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007; 120: 1731-1738.
12. Kumar B, Cordell KG, Lee JS et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26: 3128-3137.
13. Smeets SJ, Hesselink AT, Speel EJ et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 2465-2472.
14. Lau HY, Brar S, Klimowicz AC et al. Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy. Head Neck 2011; 33(2): 251-256.
15. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91(24): 2081-2086.
16. Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355(9208): 949-955.
17. Harrell FE, Lee KL, Mark DB. Tutorial in biostatistics. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
18. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
19. SAS Institute Inc. SAS Procedures Guide, Version 6 3rd ed. Cary, NC: SAS Institute Inc. 1990.
20. R development Core Team. R: A Language and Environment for Statistical Computing Vienna, Austria: R Foundation for Statistical Computing 2007. http://www.R-project.org/ (14 December 2010, date last accessed).
21. Rischin D, Young RJ, Fisher R et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-4148.
22. Gillison ML, Harris J, Westra W et al. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Oncol 2009; 27 (Suppl): 15s (Abstr 6003).
23. Licitra L, Zigon G, Gatta G et al. Human papillomavirus in HNSCC: a European epidemiologic perspective. Hematol Oncol Clin North Am 2008; 22: 1143-1153.
24. Fischer CA, Kampmann M, Zlobec I et al. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol 2010; 21: 1961-1966.
25. Chung CH, Zhang Q, Hammond EM et al. Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2010; 81(2): 331-338.